Share
USER HOTLINE: call us at +49 30 65499 145 | Not all products are available in the USA.
May 21, 2025
Third publication from the International STAR Registry on intraoperative hemoadsorption in iCABG patients on ticagrelor*

Daniel Wendt on the third publication from the International STAR Registry on intraoperative hemoadsorption in iCABG patients on ticagrelor*

Welcome to our Blog!

I want to welcome you to our official CytoSorbents Blog “Let’s talk…” and personally invite you to discuss and exchange opinions via this platform.

 

CytoSorbents’ adsorption technology represents a new approach to blood purification. As these new tools have to be used adequately to help patients in different situations, there is a need for continuous development and knowledge generation. Discussions, explanations, brainstorming and interaction in general can catalyze and accelerate this process. We will come up with interesting topics, new publications – which may even be controversial –, hypotheses, and food for thoughts to inspire and stimulate dialogue.

 

So, I want to invite all users of our products, interested healthcare professionals, researchers, thinkers, supporters, and especially critics to actively discuss and share your opinion on relevant topics to progress with the development of patient-centric precision therapy schemes.

 

I thank you in anticipation.

 

Christian

Picture of Dr. Christian Steiner
Christian Steiner, MD Executive Vice President of Sales and Marketing

All our Blog Posts

May 21, 2025
Third publication from the International STAR Registry on intraoperative hemoadsorption in iCABG patients on ticagrelor*

Daniel Wendt on the third publication from the International STAR Registry on intraoperative hemoadsorption in iCABG patients on ticagrelor*

May 05, 2025
Early and Intensive Hemoadsorption in Septic Shock: Real-World Insights from a Single-Center Study

This large, single-center study — conducted over seven years (2016-2023) — reviewed outcomes in 175 septic shock patients treated with CytoSorb. It represents the most extensive dataset from a single center to date, offering a real-world look at how timing and intensity of treatment can influence survival.

April 14, 2025
Targeted Use of CytoSorb® in Septic Shock Linked to Reduced Mortality and Vasopressor Need – New Meta-Analysis

A newly published meta-analysis by Steindl et al. in J Clin Med (2025;14:2285) presents compelling evidence for the effectiveness of CytoSorb hemoadsorption therapy in patients with septic shock — a patient group not yet targeted specifically in prior meta-analyses.

February 28, 2025
Extracorporeal Blood Purification in Septic Shock: A Review of the position paper by Bottari et al.

The Role of Extracorporeal Blood Purification Techniques in the Treatment of Septic Shock: a review based on the recent position paper by Bottari et al (1), with particular consideration of CytoSorb hemoadsorption therapy

January 27, 2025
Prof. Daniel Wendt on the results of the second interim STAR Registry analysis

Prof Dr Daniel Wendt on the results of the second interim STAR Registry analysis: “Hemoadsorption appears to be a feasible, safe and potentially effective solution for reducing perioperative bleeding in patients on oral anticoagulants”

July 08, 2024
Achieved: 1,000 entries in CytoSorb Literature Database

The CytoSorb Literature Database has just surpassed 1,000 entries – One thousand peer reviewed publications, poster presentations from national and international conferences and case reports from many different hospitals worldwide. As such, CytoSorb stands as the most researched and published hemoadsorption therapy of its kind.

CytoSorbents

Voices around the world

world map
Cardiovascular
Prof. Dr. Jurij Kalisnik
Klagenfurt, Austria

So for me, if the indication is right, this supportive therapy helps a lot.

Critical Care
Prof. Dorel Sandec
Timisoara, Romania

We treated more than 75 patients with CytoSorb® because we realized, we feel, we see, we measure a significant effect on the evolution of the patient.

Cardiovascular
Prof. Dr. Yeong-Hoon Choi
Bad Nauheim, Germany

We were able to decrease the need for circulatory supporting medications accordingly, very, very quickly to a tolerable level.